EcoDrugPlus

Bcl2 Like 2

Ensembl ID : ENSDLEG00000019924
Gene Symbol: BCL2L2
4 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSDLEG00000006834
Gene Symbol: BCL2A1
3 Cross references
133 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSDLEG00000016644
Gene Symbol: BCR
3 Cross references
286 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSDLEG00000001840
Gene Symbol: BTK
3 Cross references
207 Possible Orthologues:

C-C Chemokine Receptor Type 1

Ensembl ID : ENSDLEG00000012646
Gene Symbol: LOC111174479
3 Cross references
158 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSDLEG00000012641
Gene Symbol: CCR2
1 Cross references
150 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSDLEG00000017153
Gene Symbol: CCR4
3 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSDLEG00000012636
Gene Symbol: CCR5
4 Cross references
152 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSDLEG00000012686
Gene Symbol: CCR9
1 Cross references
265 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSDLEG00000015276
Gene Symbol: CXCL8
3 Cross references
179 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSDLEG00000011899
Gene Symbol: CXCR2
3 Cross references
269 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSDLEG00000017074
Gene Symbol: CXCR4
3 Cross references
218 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).